홈 > 시장보고서 > 의료기기

시장보고서

상품코드

1347967

세계의 아페레시스 시장(2023-2030년)

Global Apheresis Market - 2023-2030

발행일: 2023년 09월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 186 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

개요

세계의 아페레시스 시장은 2022년에 18억 달러에 달하며, 2023-2030년의 예측 기간 중 CAGR 8.4%로 성장하며, 2030년에는 50억 달러에 달할 것으로 예측되고 있습니다.

아페레시스는 사람의 혈액에서 특정 성분을 분리, 추출, 채취하는 의료 기술 의료 시술입니다. 기기 출시 증가와 혈액 질환 증가가 시장 성장의 원동력이 될 것으로 예상됩니다.

북미가 시장 점유율에서 큰 위치를 차지할 것으로 예상됩니다. 플라즈마 페리시스 부문이 큰 시장 점유율을 차지하고 있습니다. 장비의 기술 발전과 장점 증가로 인해 이 부문이 중요한 위치를 차지하고 있습니다.

DataM Intelligence에 따르면 아페레시스 시장 조사 분석은 정량적 및 정성적 데이터를 포함한 시장의 상세한 전망을 제공합니다. 시장 세분화를 기반으로 한 세계 시장 전망과 예측을 제공합니다.

다이나믹스

기기 출시 수 증가가 시장 성장을 촉진할 것으로 전망

장비의 출시 증가는 시장 성장을 가속할 것으로 예상됩니다. 예를 들어 의료 기술 기업 테루모 혈액 및 세포 기술(Terumo BCT)은 2022년 9월 20일 세포 및 유전자 치료(CGT) 분야의 공정 개발부터 상업적 생산까지 지원하는 바이오 리액터 플랫폼인 'Quantum Flex Cell Expansion System'을 발표했습니다.

또한 테르모 블러드 앤 셀 테크놀러지스(Thermo Blood and Cell Technologies)는 2023년 8월 1일, 한 번의 원심분리로 혈액을 혈소판으로 가공하는 레베오스(Reveos) 장비를 출시하고 미국 식품의약국(FDA)의 승인을 획득했습니다. 이러한 출시 증가가 시장 성장의 원동력이 될 것으로 예상됩니다.

혈액질환 증가가 시장 성장을 촉진할 것으로 예상됨

혈액 질환 증가가 시장 성장의 원동력이 될 것으로 예상됩니다. 예를 들어 CDC에 따르면 겸상적혈구증은 약 10만 명의 미국인이 앓고 있습니다. 겸상적혈구증은 흑인 또는 아프리카계 미국인 출생아 365명당 1명꼴로 발생합니다. 히스패닉계 미국인 출생아 16,300명당 1명꼴로 발생합니다. 흑인 또는 아프리카계 미국인 아기 13명 중 1명은 겸상적혈구형질(SCT)을 가지고 태어납니다.

적혈구 교환술은 뇌졸중, 급성 흉부 증후군과 같은 겸상적혈구증후군의 심각한 합병증을 치료하고 예방하는 데 사용됩니다. 적혈구 교환은 질병이나 이상이 있는 적혈구를 적출하여 공여자의 적혈구와 교환하는 방법입니다. 또한 미국 암협회가 추산한 2023년 미국내 백혈병 추정치는 약 59,610명의 백혈병(모든 유형) 신규 환자, 23,710명의 백혈병(모든 유형) 사망자, 20,380명의 급성 골수성 백혈병(AML) 신규 환자입니다. 백혈구 절제술은 순환혈액에서 환자의 백혈구를 제거하는 것입니다.

아페레시스에 따른 높은 비용이 시장 성장의 걸림돌로 작용할 것으로 예상됨

이러한 시술의 높은 비용도 시장 성장을 억제하는 주요 요인입니다. 예를 들어 플라즈마 페레시스의 평균 비용은 1회당 1,500달러에서 2,500달러 사이입니다. 아페레시스 시술에는 여러 가지 위험이 따르는데, 그 중 가장 중요한 것은 혈액 오염이며, 이는 시술 중에 매우 흔하게 발생합니다.

아페레시스와 관련된 다른 합병증도 시장 성장에 영향을 미칠 수 있습니다. 가장 흔한 아펠레시스 관련 반응은 구연산염 항응고제로 인한 저칼슘혈증으로, 일반적으로 경미하지만 기증자에게 심각한 손상을 입힐 수 있습니다. 반복적인 아펠레시스 투여는 골 탈회 및 백내장 형성과 같은 장기적인 부작용을 초래할 수 있습니다. 따라서 위의 요인은 시장 성장을 저해할 것으로 예상됩니다.

Overview

Global Apheresis Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 5.0 billion by 2030, growing with a CAGR of 8.4% during the forecast period 2023-2030.

Apheresis is a medical technology medical procedure that involves the separation, extraction, and collection of specific components of a person's blood. The increased number of launches of the devices and an increase in hematological disorders are expected to drive market growth.

North America region is expected to hold a significant position in the market share. The plasmapheresis segment holds a significant market share. The increase in technological advancements in the Devices and their advantages are holding the segment in a significant position.

As per DataM Intelligence, Apheresis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation.

Dynamics

Increased Number of Device Launches is Expected to Drive the Market Growth

An increased number of Device launches are expected to drive the market growth. For instance, on September 20, 2022, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector.

Additionally, for instance, on August 1, 2023, Terumo Blood and Cell Technologies launched a Reveos device that processes blood into platelets in a single centrifugation cycle, which has been cleared by the US Food and Drug Administration (FDA). Thus, an increase in the number of launches is expected to drive the market growth.

Increase in Hematological Disorders is Expected to Drive Market Growth

An increase in hematological disorders is expected to drive market growth. For instance, according to the CDC, Sickle Cell Disease affects approximately 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African-American births. It occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).

Red blood cell exchange is used to treat or sometimes prevent serious complications of sickle cell disease, such as stroke and acute chest syndrome. In red blood cell exchange, diseased or abnormal red blood cells are removed by apheresis and then replaced by donor red blood cells. Additionally, The American Cancer Society's estimates for leukemia in the United States for 2023 are about 59,610 new cases of leukemia (all kinds) and 23,710 deaths from leukemia (all kinds), 20,380 new cases of acute myeloid leukemia (AML). Leukapheresis involves the removal of a patient's white blood cells from the circulating blood. Thus, the increase in hematological disorders

High costs Associated with Apheresis are Expected to Hamper the Market Growth

The high cost of these procedures is also a big factor restraining the growth of the market. For instance, the average cost of plasmapheresis ranges between $1,500 and $2,500 per procedure. Various risks are associated with the Apheresis procedure, and the crucial one is blood contamination, which is very common during the procedure.

Other complications with the apheresis can also affect the market growth. The most common apheresis-specific reaction is hypocalcemia due to citrate anticoagulation, which, while usually mild, has the potential to injure the donor severely. Repeated apheresis donation may produce adverse long-term effects in donors, such as bone demineralization and cataract formation. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global apheresis market is segmented based on device, technology, procedure, and region.

Centrifugation Segment Holds a Significant Position in the Market Share

Centrifugal apheresis can be used to remove cellular components and is very efficient, achieving plasma extraction of nearly 80%. One of the benefits of centrifugal apheresis is that it requires lower blood flow rates and, therefore, can be performed using either peripheral or central venous access.

Most apheresis devices use centrifugation and require blood flow rates of 50-120 mL/min. Centrifugation takes advantage of the different specific gravities inherent to various blood products, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma. Thus, the advantages and efficiency of the centrfugation in seperating the whole blood components is holding a dominant position in the market share.

Geographical Penetration

North America region holds the largest market share in the global Apheresis market

North America holds a significant share of the global apheresis market. The increase in the number of blood transfusions and the increase in the demand for various blood components are holding the region's market growth. For instance, according to the American National Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S., nearly 5,000 units of platelets and 6,500 units of plasma are needed daily in the U.S., and about 16 million blood components are transfused each year in the U.S.

Additionally, according to the American Cancer Society, more than 1.9 million people are expected to be diagnosed with cancer in 2023. Many of them will need blood, sometimes daily, during their chemotherapy treatment. Thus, an increase in the demand for blood transfusions in the region is expected to hold the region in the dominant position.

Competitive Landscape

The global apheresis market is fragmented, with the presence of many local and international players. Fresenius SE & Co. KGaA, Cerus Corporation, Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, B. Braun, Melsungen, Kaneka Corporation, Terumo BCT, Inc., Kawasumi Laboratories Inc., and Nikkiso Europe GmbH, Baxter. are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The COVID-19 epidemic is expected to benefit the development of the global apheresis business. Global healthcare systems were under pressure from the COVID-19 epidemic. Due to COVID-19, patients with severe infections had complications with their coagulation parameters, including platelet count, fibrinogen, D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT). As a result, plasma therapy was used extensively as a treatment. Patients who contracted the COVID-19 virus are treated with convalescent plasma (CP).

By Device

Apheresis Devices
Plasma Separators
Plasma Component Separators
Immunoadsorption Columns
Plasma Perfusion Columns
Hemoperfusion Columns
Apheresis Disposables

By Technology

Centrifugation
Intermittent Flow
Continuous Flow
Membrane Separation

By Procedure

Plasmapheresis
Plateletpheresis
Erythrocytapheresis
Leukapheresis
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Why Purchase the Report?

To visualize the global apheresis market segmentation based on device, technology, procedure, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of apheresis market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Device mapping available as excel consisting of key Devices of all the major players.

The global apheresis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device
3.2. Snippet by Technology
3.3. Snippet by Procedure
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased number of device launches
  - 4.1.1.2. Increase in hematological disorders
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with apheresis
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Device

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 7.1.2. Market Attractiveness Index, By Device
7.2. Apheresis Devices *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Plasma Separators
7.4. Plasma Component Separators
7.5. Immunoadsorption Columns
7.6. Plasma Perfusion Columns
7.7. Hemoperfusion Columns
7.8. Apheresis Disposables

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Centrifugation *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intermittent Flow
8.4. Continuous Flow
8.5. Membrane Separation

9. By Procedure

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 9.1.2. Market Attractiveness Index, By Procedure
9.2. Plasmapheresis*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Plateletpheresis
9.4. Erythrocytapheresis
9.5. Leukapheresis
9.6. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Fresenius SE & Co. KGaA *
- 12.1.1. Company Overview
- 12.1.2. Device Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Cerus Corporation
12.3. Asahi Kasei Medical Co., Ltd.
12.4. Haemonetics Corporation
12.5. B. Braun Melsungen
12.6. Kaneka Corporation
12.7. Terumo BCT, Inc.
12.8. Kawasumi Laboratories Inc.
12.9. Nikkiso Europe GmbH
12.10. Baxter.

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,142,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,848,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,084,000

※ 부가세 별도